All In Biotech

Drug Trial Radar · NCT00123942

Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease

Phase I Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease

Last checked: Nov 20, 2026Latest source record: Jun 14, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

31

Planned (sponsor's estimate)

Start

Apr 2004

Primary completion

Not stated

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 26, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to determine the maximum tolerated dose (MTD) and safety and tolerability of MEDI-507 in patients with CD2-positive lymphoproliferative disorders.

Conditions

  • Lymphoproliferative Disorders

Interventions

  • MEDI-507Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the maximum tolerated dose (MTD) or the optimal biological dose
  2. (OBD) of MEDI-507 based on safety and tolerability of MEDI-507 in patients with
  3. CD-2 positive lymphoproliferative disorders.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Cancer Institute/National Institutes of Health

    Bethesda, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.